001     143356
005     20240229121829.0
024 7 _ |a pmid:30896328
|2 pmid
024 7 _ |a 1942-325X
|2 ISSN
024 7 _ |a 1942-3268
|2 ISSN
024 7 _ |a 2574-8300
|2 ISSN
024 7 _ |a altmetric:57667833
|2 altmetric
024 7 _ |a doi:10.1161/CIRCGEN.119.002470
|2 doi
037 _ _ |a DKFZ-2019-00944
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Patel, Riyaz
|b 0
245 _ _ |a Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium.
260 _ _ |a Philadelphia, Pa.
|c 2019
|b Lippincott, Williams & Wilkins
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1616066747_16560
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The 'GENetIcs of sUbSequent Coronary Heart Disease' (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD.The consortium currently includes 57 studies from 18 countries, recruiting 185,614 participants with either acute coronary syndrome, stable CHD or a mixture of both at baseline. All studies collected biological samples and followed-up study participants prospectively for subsequent events.Enrollment into the individual studies took place between 1985 to present day with duration of follow up ranging from 9 months to 15 years. Within each study, participants with CHD are predominantly of self-reported European descent (38%-100%), mostly male (44%-91%) with mean ages at recruitment ranging from 40 to 75 years. Initial feasibility analyses, using a federated analysis approach, yielded expected associations between age (HR 1.15 95% CI 1.14-1.16) per 5-year increase, male sex (HR 1.17, 95% CI 1.13-1.21) and smoking (HR 1.43, 95% CI 1.35-1.51) with risk of subsequent CHD death or myocardial infarction, and differing associations with other individual and composite cardiovascular endpoints.GENIUS-CHD is a global collaboration seeking to elucidate genetic and non-genetic determinants of subsequent event risk in individuals with established CHD, in order to improve residual risk prediction and identify novel drug targets for secondary prevention. Initial analyses demonstrate the feasibility and reliability of a federated analysis approach. The consortium now plans to initiate and test novel hypotheses as well as supporting replication and validation analyses for other investigators.
536 _ _ |a 323 - Metabolic Dysfunction as Risk Factor (POF3-323)
|0 G:(DE-HGF)POF3-323
|c POF3-323
|f POF III
|x 0
588 _ _ |a Dataset connected to PubMed,
700 1 _ |a Tragante, Vinicius
|b 1
700 1 _ |a Schmidt, Amand F
|b 2
700 1 _ |a McCubrey, Raymond O
|b 3
700 1 _ |a Holmes, Michael V
|b 4
700 1 _ |a Howe, Laurence J
|b 5
700 1 _ |a Direk, Kenan
|b 6
700 1 _ |a Åkerblom, Axel
|b 7
700 1 _ |a Leander, Karin
|b 8
700 1 _ |a Virani, Salim S
|b 9
700 1 _ |a Kaminski, Karol A
|b 10
700 1 _ |a Muehlschlegel, Jochen D
|b 11
700 1 _ |a Allayee, Hooman
|b 12
700 1 _ |a Almgren, Peter
|b 13
700 1 _ |a Alver, Maris
|b 14
700 1 _ |a Baranova, Ekaterina V
|b 15
700 1 _ |a Behlouli, Hassan
|b 16
700 1 _ |a Boeckx, Bram
|b 17
700 1 _ |a Braund, Peter S
|b 18
700 1 _ |a Breitling, Lutz P
|b 19
700 1 _ |a Delgado, Graciela
|b 20
700 1 _ |a Duarte, Nubia E
|b 21
700 1 _ |a Dubé, Marie-Pierre
|b 22
700 1 _ |a Dufresne, Line
|b 23
700 1 _ |a Eriksson, Niclas
|b 24
700 1 _ |a Foco, Luisa
|b 25
700 1 _ |a Scholz, Markus
|b 26
700 1 _ |a Gijsberts, Crystel M
|b 27
700 1 _ |a Glinge, Charlotte
|b 28
700 1 _ |a Gong, Yan
|b 29
700 1 _ |a Hartiala, Jaana
|b 30
700 1 _ |a Heydarpour, Mahyar
|b 31
700 1 _ |a Hubacek, Jaroslav A
|b 32
700 1 _ |a Kleber, Marcus
|b 33
700 1 _ |a Kofink, Daniel
|b 34
700 1 _ |a Kotti, Salma
|b 35
700 1 _ |a Kuukasjärvi, Pekka
|b 36
700 1 _ |a Lee, Vei-Vei
|b 37
700 1 _ |a Leiherer, Andreas
|b 38
700 1 _ |a Lenzini, Petra A
|b 39
700 1 _ |a Levin, Daniel
|b 40
700 1 _ |a Lyytikäinen, Leo-Pekka
|b 41
700 1 _ |a Martinelli, Nicola
|b 42
700 1 _ |a Mons, Ute
|0 P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9
|b 43
|u dkfz
700 1 _ |a Nelson, Christopher P
|b 44
700 1 _ |a Nikus, Kjell
|b 45
700 1 _ |a Pilbrow, Anna P
|b 46
700 1 _ |a Ploski, Rafal
|b 47
700 1 _ |a Sun, Yan V
|b 48
700 1 _ |a Tanck, Michael W T
|b 49
700 1 _ |a Tang, W H Wilson
|b 50
700 1 _ |a Trompet, Stella
|b 51
700 1 _ |a van der Laan, Sander W
|b 52
700 1 _ |a Van Setten, Jessica
|b 53
700 1 _ |a Vilmundarson, Ragnar O
|b 54
700 1 _ |a Viviani Anselmi, Chiara
|b 55
700 1 _ |a Vlachopoulou, Efthymia
|b 56
700 1 _ |a Al Ali, Lawien
|b 57
700 1 _ |a Boerwinkle, Eric
|b 58
700 1 _ |a Briguori, Carlo
|b 59
700 1 _ |a Carlquist, John F
|b 60
700 1 _ |a Carruthers, Kathryn F
|b 61
700 1 _ |a Casu, Gavino
|b 62
700 1 _ |a Deanfield, John
|b 63
700 1 _ |a Deloukas, Panos
|b 64
700 1 _ |a Dudbridge, Frank
|b 65
700 1 _ |a Engström, Thomas
|b 66
700 1 _ |a Fitzpatrick, Natalie
|b 67
700 1 _ |a Fox, Kim
|b 68
700 1 _ |a Gigante, Bruna
|b 69
700 1 _ |a James, Stefan
|b 70
700 1 _ |a Lokki, Marja-Liisa
|b 71
700 1 _ |a Lotufo, Paulo A
|b 72
700 1 _ |a Marziliano, Nicola
|b 73
700 1 _ |a Mordi, Ify R
|b 74
700 1 _ |a Muhlestein, Joseph B
|b 75
700 1 _ |a Newton-Cheh, Christopher
|b 76
700 1 _ |a Pitha, Jan
|b 77
700 1 _ |a Saely, Christoph H
|b 78
700 1 _ |a Samman-Tahhan, Ayman
|b 79
700 1 _ |a Sandesara, Pratik B
|b 80
700 1 _ |a Teren, Andrej
|b 81
700 1 _ |a Timmis, Adam
|b 82
700 1 _ |a Van de Werf, Frans
|b 83
700 1 _ |a Wauters, Els
|b 84
700 1 _ |a Wilde, Arthur A M
|b 85
700 1 _ |a Ford, Ian
|b 86
700 1 _ |a Stott, David J
|b 87
700 1 _ |a Algra, Ale
|b 88
700 1 _ |a Andreassi, Maria G
|b 89
700 1 _ |a Ardissino, Diego
|b 90
700 1 _ |a Arsenault, Benoit J
|b 91
700 1 _ |a Ballantyne, Christie M
|b 92
700 1 _ |a Bergmeijer, Thomas O
|b 93
700 1 _ |a Bezzina, Connie R
|b 94
700 1 _ |a Body, Simon C
|b 95
700 1 _ |a Boersma, Eric H
|b 96
700 1 _ |a Bogaty, Peter
|b 97
700 1 _ |a Bots, Michiel
|b 98
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 99
|u dkfz
700 1 _ |a Brugts, Jasper J
|b 100
700 1 _ |a Burkhardt, Ralph
|b 101
700 1 _ |a Carpeggiani, Clara
|b 102
700 1 _ |a Condorelli, Gianluigi
|b 103
700 1 _ |a Cooper-DeHoff, Rhonda M
|b 104
700 1 _ |a Cresci, Sharon
|b 105
700 1 _ |a Danchin, Nicolas
|b 106
700 1 _ |a de Faire, Ulf
|b 107
700 1 _ |a Doughty, Robert N
|b 108
700 1 _ |a Drexel, Heinz
|b 109
700 1 _ |a Engert, James C
|b 110
700 1 _ |a Fox, Keith A A
|b 111
700 1 _ |a Girelli, Domenico
|b 112
700 1 _ |a Grobbee, Diederick E
|b 113
700 1 _ |a Hagström, Emil
|b 114
700 1 _ |a Hazen, Stanley L
|b 115
700 1 _ |a Held, Claes
|b 116
700 1 _ |a Hemingway, Harry
|b 117
700 1 _ |a Hoefer, Imo E
|b 118
700 1 _ |a Hovingh, G Kees
|b 119
700 1 _ |a Jabbari, Reza
|b 120
700 1 _ |a Johnson, Julie A
|b 121
700 1 _ |a Jukema, J Wouter
|b 122
700 1 _ |a Kaczor, Marcin P
|b 123
700 1 _ |a Kähönen, Mika
|b 124
700 1 _ |a Kettner, Jiri
|b 125
700 1 _ |a Kiliszek, Marek
|b 126
700 1 _ |a Klungel, Olaf H
|b 127
700 1 _ |a Lagerqvist, Bo
|b 128
700 1 _ |a Lambrechts, Diether
|b 129
700 1 _ |a Laurikka, Jari O
|b 130
700 1 _ |a Lehtimäki, Terho
|b 131
700 1 _ |a Lindholm, Daniel
|b 132
700 1 _ |a Mahmoodi, B. K.
|b 133
700 1 _ |a Maitland-van der Zee, Anke H
|b 134
700 1 _ |a McPherson, Ruth
|b 135
700 1 _ |a Melander, Olle
|b 136
700 1 _ |a Metspalu, Andres
|b 137
700 1 _ |a Niemcunowicz-Janica, Anna
|b 138
700 1 _ |a Olivieri, Oliviero
|b 139
700 1 _ |a Opolski, Grzegorz
|b 140
700 1 _ |a Palmer, Colin N
|b 141
700 1 _ |a Pasterkamp, Gerard
|b 142
700 1 _ |a Pepine, Carl J
|b 143
700 1 _ |a Pereira, Alexandre C
|b 144
700 1 _ |a Pilote, Louise
|b 145
700 1 _ |a Quyyumi, Arshed A
|b 146
700 1 _ |a Richards, A Mark
|b 147
700 1 _ |a Sanak, Marek
|b 148
700 1 _ |a Siegbahn, Agneta
|b 149
700 1 _ |a Simon, Tabassome
|b 150
700 1 _ |a Sinisalo, Juha
|b 151
700 1 _ |a Smith, J Gustav
|b 152
700 1 _ |a Spertus, John A
|b 153
700 1 _ |a Stender, Steen
|b 154
700 1 _ |a Stewart, Alexandre F R
|b 155
700 1 _ |a Szczeklik, Wojciech
|b 156
700 1 _ |a Szpakowicz, Anna
|b 157
700 1 _ |a Tardif, Jean-Claude
|b 158
700 1 _ |a Ten Berg, Jurriën M
|b 159
700 1 _ |a Tfelt-Hansen, Jacob
|b 160
700 1 _ |a Thanassoulis, George
|b 161
700 1 _ |a Thiery, Joachim
|b 162
700 1 _ |a Torp-Pedersen, Christian
|b 163
700 1 _ |a van der Graaf, Yolanda
|b 164
700 1 _ |a Visseren, Frank L J
|b 165
700 1 _ |a Waltenberger, Johannes
|b 166
700 1 _ |a Weeke, Peter E
|b 167
700 1 _ |a Van der Harst, Pim
|b 168
700 1 _ |a Lang, Chim C
|b 169
700 1 _ |a Sattar, Naveed
|b 170
700 1 _ |a Cameron, Vicky A
|b 171
700 1 _ |a Anderson, Jeffrey L
|b 172
700 1 _ |a Brophy, James M
|b 173
700 1 _ |a Paré, Guillaume
|b 174
700 1 _ |a Horne, Benjamin D
|b 175
700 1 _ |a März, Winfried
|b 176
700 1 _ |a Wallentin, Lars
|b 177
700 1 _ |a Samani, Nilesh J
|b 178
700 1 _ |a Hingorani, Aroon D
|b 179
700 1 _ |a Asselbergs, Folkert W
|b 180
773 _ _ |a 10.1161/CIRCGEN.119.002470
|0 PERI:(DE-600)2457085-0
|n 4
|p e002470
|t Circulation Genomic and precision medicine [...]
|v 12
|y 2019
|x 2574-8300
909 C O |p VDB
|o oai:inrepo02.dkfz.de:143356
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 43
|6 P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 99
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|b Gesundheit
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-323
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Metabolic Dysfunction as Risk Factor
|x 0
913 2 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CIRC-CARDIOVASC GENE : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CIRC-CARDIOVASC GENE : 2017
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21